Data Sources: Studies were identified through a search of MEDLINE (1966-2000), the
Cochrane Library (issue 3, 2000), and PubMed (December 15, 2000). Reference lists of …

Introduction Cutaneous warts are highly prevalent lesions caused by the infection of
keratinocytes by different types of human papillomaviruses. Although cutaneous warts are …

Our objective was to determine the optimal duration of treatment with imiquimod for external
genital warts over 4, 8, 12 or 16 weeks. A total of 120 women with a history of genital warts …

Objective To review published randomised controlled trials to assess the benefit and harm of
imiquimod in the treatment of external genital warts. Data sources MEDLINE (1966 …

Genital warts affect at least 1% of sexually active adults. Current therapies are inadequate
because they are often painful, may fail to prevent recurrence and transmission of warts, and …

The purpose of this randomized, double‐blind, placebo‐controlled study was to determine
the clinical efficacy and tolerability of an analog of imiquimod (2%) in cream to cure genital …

Imiquimod is a topically active immunomodulatory agent that is formulated as a 5% cream
for application by the patient. It is the first agent of its class, the immune response modifiers …

ABSTRACT A retrospective case‐note audit of 74 patients with 81 treatment episodes of
anogenital warts with imiquimod from April 1999 until July 2000 was performed. The majority …

Patients were treated until complete resolution of baseline warts was confirmed, or for up to
16 weeks, and then entered a 4-week observation period. Patients were monitored for …

Genital warts are one of the most common sexually transmitted diseases worldwide. The
disease is a result of infection with low-risk types of human papillomaviruses, mostly type 6 …